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Virological conﬁrmationDengue virus (DENV) is estimated to infect approximately
400 million people annually. In 2014, 160 cases of autochthonous
and 173 imported DENV infection cases were conﬁrmed in Japan.1
Concurrent infection by two DENV serotypes is not an uncommon
event in dengue hyperendemic areas where several DENV
serotypes co-circulate.2 However, neither of the studies by
previous investigators has clearly conﬁrmed concurrent infection
by virus isolation and separation.2,3 In the present study, we
identiﬁed and conﬁrmed a case of concurrent DENV-1 and DENV-4
infection in a patient by a method of virus isolation and separation
for concurrent infection, using an Fc-gamma receptor (FcgR)-
expressing BHK cell line.4 The results present evidence of the
presence of infectious virus particles of two virus serotypes in a
patient.Table 1
Virus isolation using FcgR-expressing cells and neutralizing antibodya
Passage
number
Sample
number
Isolation method 
0 Patient None (patient serum sa
1 1-1* 10 ml serum sample + 1
1-2 10 ml serum sample + 1
2 1-2-1 10 ml supernatant + 10 m
1-2-2 10 ml supernatant + 10 m
1-2-3 1 ml supernatant + 10 m
1-2-4 1 ml supernatant + 10 m
1-2-5 10 ml supernatant + 10 m
1-2-6 1 ml supernatant + 10 m
1-2-7 50 ml supernatant only
3 1-2-3-1 10 ml supernatant + 10 m
1-2-3-2 10 ml supernatant + 10 m
1-2-3-3* 1 ml supernatant + 10 m
1-2-3-4 1 ml supernatant + 10 m
1-2-3-5 0.5 ml supernatant + 10 
1-2-3-6 0.5 ml supernatant + 10 
1-2-3-7 0.1 ml supernatant + 10 
1-2-3-8 0.1 ml supernatant + 10 
1-2-3-9 10 ml supernatant + 10 m
1-2-3-10 10 ml supernatant + 10 m
1-2-3-11 1 ml supernatant + 10 m
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A serum sample from a dengue patient who returned to Japan
from a visit to Cambodia in 2013, was positive for DENV-1
(genotype 1; Genbank Accession number AB873104) and DENV-4
(genotype 1; Genbank Accession number AB873105) virus
genome, and negative for anti-DENV IgM and IgG.5 Initial attempts
to isolate and separate DENV using non FcgR-expressing Vero
and BHK cells resulted in the isolation of DENV-1 only. To isolate
DENV-4, the patient’s serum sample was treated with pooled
human serum samples with neutralizing activity to DENV-1 but
not to DENV-4 (DENV-1 PRNT50 1:10, DENV-4 PRNT50 < 10; as
determined by FcgR-expressing BHK cells).6 DENV-1 and DENV-4
strains were isolated and separated, and conﬁrmed by RT-PCR and
sequencing of the E-protein gene7 (Table 1).
Neutralizing antibodies to one DENV serotype may possess
antibody-dependent enhancement (ADE) activity to heterolo-
gous serotypes in FcgR-positive cells, resulting in higher levels of
progeny virus production.8 ADE activity also hampers serotype
cross-reactive neutralizing antibody titers in FcgR-expressing
cells but not in FcgR-negative cells.6 In the present study, both
neutralization and the ADE mechanism were applied to virus
isolation in a concurrent infection using FcgR-expressing cells.
The serotype cross-reactive pooled serum samples used in thisLog10 genome copies/ml
DENV-1 DENV-4
mple) 9.8 6.1
0 ml 1:10 Nt Ab 7.5 -
0 ml 1:10 Nt Ab 6.0 7.3
l 1:10 Nt Ab 8.8 8.6
l 1:10 Nt Ab 4.0 -
l 1:10 Nt Ab 4.4 8.2
l 1:10 Nt Ab 5.0 -
l undiluted Nt Ab 7.4 8.5
l undiluted Nt Ab 4.9 7.9
 10.0 8.1
l 1:10 Nt Ab - 8.4
l 1:10 Nt Ab - 8.8
l 1:10 Nt Ab - 8.0
l 1:10 Nt Ab - 8.5
ml 1:10 Nt Ab - 8.2
ml 1:10 Nt Ab - 8.3
ml 1:10 Nt Ab - 7.8
ml 1:10 Nt Ab - 8.1
l undiluted Nt Ab - 8.6
l undiluted Nt Ab - 8.8
l undiluted Nt Ab - 8.0
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Table 1 (Continued )
Passage
number
Sample
number
Isolation method Log10 genome copies/ml
DENV-1 DENV-4
1-2-3-12 1 ml supernatant + 10 ml undiluted Nt Ab - 8.5
1-2-3-13 0.5 ml supernatant + 10 ml undiluted Nt Ab - 7.9
1-2-3-14 0.5 ml supernatant + 10 ml undiluted Nt Ab - 8.5
1-2-3-15 0.1 ml supernatant + 10 ml undiluted Nt Ab - 7.8
1-2-3-16 0.1 ml supernatant + 10 ml undiluted Nt Ab - 7.9
1-2-3-17 10 ml supernatant only - 8.7
FcgR, Fc-gamma receptor; DENV, dengue virus.
a Use of non-FcgR-expressing Vero cells for virus isolation in the ﬁrst passage resulted in the isolation of DENV-1 isolate only, as determined by conventional RT-PCR. In the
presence of neutralizing antibodies, only DENV-1 was isolated (10 ml supernatant + 10 ml 1:10 Nt Ab, DENV-1 = 6.6 log10 genome copies/ml; 1 ml supernatant + 10 ml 1:10 Nt
Ab, DENV-1 = 4.7 log10 genome copies/ml) using sample 1-2, by BHK cells. ‘Nt Ab’ denotes pooled sera with neutralizing activity to DENV-1 but not to DENV-4 using FcgR-
expressing cells as assay cells; ‘-’ denotes ‘not detected’; underlined numbers indicate supernatant used for further passage (supernatant with a low DENV-1 titer and a high
DENV-4 titer was chosen for further passage); ‘*’ indicates sample used for sequencing and comparison to the DENV-1 and DENV-4 sequences of serum sample. The E-protein
sequences of the DENV-1 (sample number 1-1) and DENV-4 (sample number 1-2-3-3) isolates were 100% identical to those DENV-1 and DENV-4 sequences using serum
samples.
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DENV-1 but no neutralizing activity to DENV-4 using FcgR-
expressing cells as assay cells.6 Thus, serotype-speciﬁc anti-
bodies speciﬁcally neutralized the dominant DENV-1 serotype
and may have enhanced the growth of the subdominant DENV-4
serotype.
In conclusion, this report provides concrete evidence of
concurrent DENV infection by multiple DENV serotypes in a DENV
patient, and presents evidence on the potential of viremic travelers
to introduce more than a single virus serotype to the local
mosquito vector population.9,10
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